NMDA Receptor Antagonists
| Cat. No. | Product Name / Activity |
|---|---|
| 3693 | DL-AP5 Sodium salt |
| Potent and selective NMDA antagonist; sodium salt of DL-AP5 | |
| 0106 | D-AP5 |
| Potent and selective NMDA receptor antagonist; more active form of DL-AP5 | |
| 0105 | DL-AP5 |
| Potent and selective NMDA antagonist | |
| 0107 | L-AP5 |
| Potent and selective NMDA antagonist; less active form of DL-AP5 | |
| 4492 | Cerestat |
| Potent and noncompetitive NMDA antagonist | |
| 1469 | CGP 37849 |
| Potent and selective NMDA antagonist | |
| 1409 | CGP 39551 |
| Potent, selective and competitive NMDA antagonist | |
| 1493 | CGP 78608 hydrochloride |
| Potent and selective NMDA antagonist; acts at glycine site | |
| 1241 | CGS 19755 |
| Potent competitive NMDA antagonist | |
| 3697 | 7-Chlorokynurenic acid sodium salt |
| Sodium salt of 7-Chlorokynurenic acid | |
| 0237 | 7-Chlorokynurenic acid |
| NMDA antagonist; acts at glycine site | |
| 0190 | CNQX |
| NMDA antagonist; acts at glycine site; also AMPA/kainate antagonist | |
| 2456 | Co 101244 hydrochloride |
| GluN2B-selective NMDA antagonist | |
| 0247 | (R)-CPP |
| Potent NMDA antagonist; more active enantiomer of (RS)-CPP | |
| 0173 | (RS)-CPP |
| Potent NMDA antagonist | |
| 1265 | D-CPP-ene |
| Potent competitive NMDA antagonist | |
| 0286 | 5,7-Dichlorokynurenic acid |
| Potent NMDA antagonist; acts at glycine site | |
| 3698 | 5,7-Dichlorokynurenic acid sodium salt |
| Potent NMDA antagonist, acts at glycine site; sodium salt of 5,7-Dichlorokynurenic acid | |
| 4491 | DQP 1105 |
| GluN2C/GluN2D-selective NMDA antagonist | |
| 2867 | Flupirtine maleate |
| Indirect NMDA antagonist; also GABAA modulator and Kv7 channel activator | |
| 2348 | Gavestinel |
| Potent and selective NMDA antagonist; acts at the glycine site | |
| 0545 | Ifenprodil hemitartrate |
| Non-competitive NMDA antagonist; also σ ligand | |
| 2892 | threo Ifenprodil hemitartrate |
| GluN2B-selective NMDA antagonist; also σ agonist | |
| 3131 | Ketamine hydrochloride |
| Non-competitive NMDA antagonist | |
| 6751 | (R)-(-)-Ketamine hydrochloride |
| NMDA antagonist; antidepressant; may not display psychotomimetic or addictive side effects of (S)-ketamine | |
| 4379 | (S)-(+)-Ketamine hydrochloride |
| NMDA antagonist; enantiomer of ketamine hydrochloride | |
| 0742 | L-689,560 |
| Highly potent NMDA antagonist | |
| 0705 | L-701,252 |
| NMDA antagonist; acts at glycine site | |
| 0907 | L-701,324 |
| NMDA antagonist; acts at glycine site | |
| 0840 | Loperamide hydrochloride |
| NMDA antagonist; reduces Ca2+ flux | |
| 0773 | Memantine hydrochloride |
| NMDA antagonist; acts at ion channel site | |
| 0924 | (+)-MK 801 maleate |
| Non-competitive NMDA antagonist; acts at ion channel site | |
| 0955 | (-)-MK 801 maleate |
| NMDA antagonist; less active enantiomer of (+)-MK 801 | |
| 1970 | Norketamine hydrochloride |
| Potent non-competitive NMDA antagonist; antinociceptive | |
| 5018 | PEAQX tetrasodium salt |
| Potent and GluN2A-selective NMDA antagonist | |
| 2557 | Phencyclidine hydrochloride |
| Non-competitive NMDA antagonist | |
| 2530 | PPDA |
| GluN2C/GluN2D-selective NMDA antagonist | |
| 4801 | QNZ 46 |
| Non-competitive and GluN2C/GluN2D-selective NMDA antagonist | |
| 1594 | Ro 25-6981 maleate |
| GluN2B-selective NMDA antagonist | |
| 3254 | Ro 61-8048 |
| NMDA antagonist; increases kynurenic acid levels | |
| 1250 | SDZ 220-581 |
| Competitive NMDA antagonist | |
| 4154 | TCN 201 |
| GluN1/GluN2A-selective NMDA antagonist | |
| 4163 | TCN 213 |
| NMDA antagonist; selective for GluN2A over GluN2B containing receptors |
Our product guide provides background information on Huntington's disease and highlights products that can be used to research neurodegeneration.
Request copyRequest PDF
Highlights around 500 products for ion channel research.
Request copyRequest PDF
Our Pain guide highlights over 280 products for Pain research.
Request copyRequest PDFWritten by Alan Palmer
Our Alzheimer's disease poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease.
Request copyDownload PDFWritten by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDF
Written by Alsa Pitkänen and Xavier Ekolle Ndode-Ekane, this poster summarizes current knowledge about how epilepsy develops.
Request copyDownload PDF
Our Huntington's Disease (HD) poster summarizes the pathophysiology and molecular changes that occur in HD.
Request copyDownload PDFWritten by Clea Warburton and Zafar Bashir
Our Learning and Memory poster gives an overview of the cellular mechanisms underlying recognition memory and its links to long-term depression.
Request copyDownload PDFWritten by Grant D. Nicol and Michael R. Vasko
Our Peripheral Sensitization poster gives a summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDFWritten by Justin M. Saunders and Javier González-Maeso
Our Schizophrenia poster highlights the targets and pathways representing the most promising strategies to pursue for novel drug development.
Request copyDownload PDF